This document is a published patent application (US20260083829A1) filed by Amicus Therapeutics, Inc. It claims novel compositions containing high concentrations of acid alpha-glucosidase combined with an active site-specific chaperone, intended for the treatment of Pompe disease. The application also describes methods for enhancing the stability of acid alpha-glucosidase enzyme formulations, both in vitro and in vivo.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future intellectual property protection for specific therapeutic compositions and methods related to Pompe disease treatment. Companies operating in the rare disease and enzyme replacement therapy space should be aware of this filing as it may impact their research and development strategies or potential licensing opportunities.